secwatch.observer — SEC 8-K summary
======================================

Issuer:     NovoCure Ltd (NVCR)
CIK:        0001645113
Form:       8-K
Filed at:   2023-08-28T23:59:59+00:00
Accession:  0001645113-23-000046
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NovoCure's INNOVATE-3 trial fails primary endpoint: no OS benefit in ovarian cancer
--------------------------------------------------------------------------------

- Median OS 12.2 months (TTFields + paclitaxel) vs 11.9 months (paclitaxel alone); HR 1.008.
- 540 patients enrolled; trial designed for platinum-resistant ovarian cancer.
- TTFields therapy well-tolerated without added systemic toxicities.
- Exploratory subgroup suggests potential survival benefit in patients with only one prior therapy line.
- Full data analysis ongoing; results to be shared with scientific community.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645113/000164511323000046/0001645113-23-000046-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645113/000164511323000046/nvcr-20230828.htm
  HTML page:      https://secwatch.observer/filing/0001645113-23-000046

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer